According to a new report published by Transparency Market Research, the global Kawasaki disease therapeutics market will witness a significant growth during 2017-2025, due to increase in adoption of intravenous immunoglobulin therapy. The adoption of intravenous immunoglobulin therapy is rising in order to reduce or prevent the coronary artery problems. This will drive the market for Kawasaki disease therapeutics during the forecast period, according to a report.
Previously known as a mucocutaneous lymph node syndrome, Kawasaki disease is a less frequently seen childhood disease that disturbs the blood vessels in children. It is a form of the condition called as vasculitis that encompasses inflammation of the blood vessels. Additionally, Kawasaki disease can sometime lead to cardiovascular complications where this disease affects the coronary arteries carrying oxygenated blood to the heart. But, the rate of cardiovascular complications has radically abridged with the practice of intravenous immune globulin (IVIG) therapy.
General symptoms of Kawasaki disease comprise fever that lasts for more than five days, redness on the palms and feet soles, and red eyes & lips. Numerous recommendations have been developed by the regulatory authorities to cure the disease. The most common therapeutic medications used to relieve the symptoms involve infusion of gamma globulins through intravenous route and the dosage of aspirin.
Additionally, the accentuating clinical trials using various drugs like infliximab and steroids to treat the disease as the second line and tertiary treatment show momentous prospects for the Kawasaki disease therapeutics market in the near future.
To know more about each segment of the Kawasaki disease therapeutics market and the overall market outlook, click here.
Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals. We are leaders in analytics, research, and advisory services for Fortune 500 companies, scores of high potential startups, and financial institutions. Our success stories have proven why we are a preeminent provider of cutting-edge syndicated and customized research services. Leverage the best of our seasoned research analysts who hold a keen interest and enviable expertise of almost 4 million hours in global, regional, and local market intelligence. TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.
US Office Contact
90 State Street, Suite 700
Albany, NY 12207
USA – Canada Toll Free: 866-552-3453